Nothing Special   »   [go: up one dir, main page]

PT1257260E - Formulacao de po - Google Patents

Formulacao de po

Info

Publication number
PT1257260E
PT1257260E PT01908465T PT01908465T PT1257260E PT 1257260 E PT1257260 E PT 1257260E PT 01908465 T PT01908465 T PT 01908465T PT 01908465 T PT01908465 T PT 01908465T PT 1257260 E PT1257260 E PT 1257260E
Authority
PT
Portugal
Prior art keywords
excipient
particle size
size distribution
active substance
formulation
Prior art date
Application number
PT01908465T
Other languages
English (en)
Inventor
Hendrikus Gerardus M Heijerman
Petrus Paulus Hendricus
Henderik Willem Frijlink
Anne Haaije De Boer
Original Assignee
Univ Groningen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8171037&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1257260(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Groningen filed Critical Univ Groningen
Publication of PT1257260E publication Critical patent/PT1257260E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0028Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0028Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0031Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up by bursting or breaking the package, i.e. without cutting or piercing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2206/00Characteristics of a physical parameter; associated device therefor
    • A61M2206/10Flow characteristics
    • A61M2206/16Rotating swirling helical flow, e.g. by tangential inflows

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT01908465T 2000-02-17 2001-02-19 Formulacao de po PT1257260E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00200550A EP1129705A1 (en) 2000-02-17 2000-02-17 Powder formulation for inhalation

Publications (1)

Publication Number Publication Date
PT1257260E true PT1257260E (pt) 2004-12-31

Family

ID=8171037

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01908465T PT1257260E (pt) 2000-02-17 2001-02-19 Formulacao de po

Country Status (7)

Country Link
US (1) US7344734B2 (pt)
EP (2) EP1129705A1 (pt)
AT (1) ATE271383T1 (pt)
AU (1) AU2001236207A1 (pt)
DE (1) DE60104399T2 (pt)
PT (1) PT1257260E (pt)
WO (1) WO2001060341A1 (pt)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
GB9920839D0 (en) 1999-09-04 1999-11-10 Innovata Biomed Ltd Inhaler
AR028746A1 (es) 2000-06-23 2003-05-21 Norton Health Care Ltd Cartucho de dosis previamente medidas para inhalador de polvo seco accionado por la respiracion, el inhalador y un metodo de provision de dosis previamente medidas de polvo seco
US6681768B2 (en) 2001-06-22 2004-01-27 Sofotec Gmbh & Co. Kg Powder formulation disintegrating system and method for dry powder inhalers
DE10129703A1 (de) * 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
GB0128148D0 (en) 2001-11-23 2002-01-16 Innovata Biomed Ltd Assembly
EP1494732B1 (en) 2002-03-20 2008-01-30 MannKind Corporation Inhalation apparatus
WO2003089036A1 (en) 2002-04-19 2003-10-30 3M Innovative Properties Company A spacer for inertial removal of the non-respirable fraction of medicinal aerosols
EP1556018A1 (en) * 2002-09-30 2005-07-27 Acusphere, Inc. Sustained release porous microparticles for inhalation
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1488819A1 (en) 2003-06-16 2004-12-22 Rijksuniversiteit te Groningen Dry powder inhaler and method for pulmonary inhalation of dry powder
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
CA2533887A1 (en) * 2003-09-30 2005-04-14 Acusphere, Inc. Injectable, oral, or topical sustained release pharmaceutical formulations
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
BRPI0509348A (pt) 2004-04-21 2007-09-11 Innovata Biomed Ltd inalador
GB0409197D0 (en) 2004-04-24 2004-05-26 Innovata Biomed Ltd Device
SE530006C2 (sv) * 2004-06-18 2008-02-05 Mederio Ag Inhalator som använder balja
DK1786784T3 (da) 2004-08-20 2011-02-14 Mannkind Corp Katalyse af diketopiperazinsyntese
KR20130066695A (ko) 2004-08-23 2013-06-20 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
EP3199164B1 (en) 2005-02-10 2020-03-18 Glaxo Group Limited Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
WO2007009164A1 (en) 2005-07-15 2007-01-25 Eiffel Technologies Limited Method of particle formation
DK2656836T3 (en) 2005-09-14 2017-10-23 Mannkind Corp Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
CA2631492A1 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
BRPI0707991B8 (pt) 2006-02-22 2021-05-25 Mannkind Corp métodos de preparação de um medicamento em pó seco com uma propriedade farmacêutica melhorada, dito pó seco e uso de uma quantidade efetiva do pó seco
GB0622818D0 (en) * 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
ATE544759T1 (de) 2007-07-21 2012-02-15 Albany Molecular Res Inc 5-pyridinon-substituierte indazole und pharmazeutische zusammensetzungen davon
EP2020249A1 (de) 2007-08-01 2009-02-04 Boehringer Ingelheim Pharma GmbH & Co. KG Inhalator
CA2722611A1 (en) 2007-11-21 2009-05-28 Decode Genetics Ehf Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders
AU2009204048B2 (en) 2008-01-11 2013-08-01 Harmony Biosciences Management, Inc. (1-azinone) -substituted pyridoindoles as MCH antagonists
DK2082769T3 (en) * 2008-01-24 2015-08-31 Vectura Delivery Devices Ltd inhaler
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
TWI677355B (zh) 2008-06-13 2019-11-21 美商曼凱公司 用於藥物傳輸之乾粉吸入器及系統
AU2009259883B2 (en) 2008-06-20 2015-02-05 Mannkind Corporation An interactive apparatus and method for real-time profiling of inhalation efforts
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
GB0818476D0 (en) * 2008-10-09 2008-11-12 Vectura Delivery Device Ltd Inhaler
GB201020130D0 (en) * 2010-11-26 2011-01-12 Vectura Delivery Devices Ltd Inhaler
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
WO2010060876A1 (de) * 2008-11-28 2010-06-03 Boehringer Ingelheim International Gmbh Dispergierverfahren zur bestimmung der partikelhaftkraft
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
BRPI1007350B8 (pt) 2009-01-26 2021-05-25 Israel Institute For Biological Res compostos espiro heterocíclicos bicíclicos
CA2754595C (en) 2009-03-11 2017-06-27 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
JP5859433B2 (ja) 2009-06-12 2016-02-10 マンカインド コーポレイション 規定された比表面積を有するジケトピペラジン微粒子
DE102009037840B4 (de) * 2009-08-18 2012-08-16 Gamptec Gmbh Inhalationsvorrichtung und Verfahren zur Inhalation eines Wirkstoffs aus einer Kapsel
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
GB0919465D0 (en) * 2009-11-06 2009-12-23 Norton Healthcare Ltd Airflow adaptor for a breath-actuated dry powder inhaler
AU2011271097B2 (en) 2010-06-21 2014-11-27 Mannkind Corporation Dry powder drug delivery system and methods
ES2625858T3 (es) 2011-04-01 2017-07-20 Mannkind Corporation Paquete de tipo blíster para cartuchos farmacéuticos
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
EP2776053A1 (en) 2011-10-24 2014-09-17 MannKind Corporation Methods and compositions for treating pain
JP6312262B2 (ja) 2012-07-12 2018-04-18 マンカインド コーポレイション 乾燥粉末薬物送達システム
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
KR102246914B1 (ko) 2013-03-15 2021-04-30 맨카인드 코포레이션 미세결정성 디케토피페라진 조성물 및 방법
BR112015033065B1 (pt) 2013-07-03 2022-12-20 Biopraxis Research Aie Nanopartícula de lipídio; composição farmacêutica; e uso da nanopartícula de lipídio
BR122019026637B1 (pt) 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
CN105517607A (zh) 2013-08-05 2016-04-20 曼金德公司 吹入设备和方法
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
WO2016013986A1 (en) 2014-07-25 2016-01-28 Agency For Science, Technology And Research Antibiotic compositions for treating bacterial infections
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
EP3212212B1 (en) 2014-10-31 2020-09-23 Monash University Powder formulation
AU2019240065A1 (en) 2018-03-20 2020-09-24 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
CA3111275A1 (en) 2018-09-06 2020-03-12 Innopharmascreen Inc. Methods and compositions for treatment of asthma or parkinson's disease
US20220162182A1 (en) 2018-12-31 2022-05-26 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
US12029709B2 (en) 2022-08-11 2024-07-09 De Motu Cordis Pty Ltd Inhalable epinephrine formulation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1242211A (en) * 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
US5048227A (en) * 1988-05-05 1991-09-17 Junya Okubo Method of cultivating agaricus blazei mushroom
DE4140689B4 (de) 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
DE4211475A1 (de) * 1991-12-14 1993-06-17 Asta Medica Ag Pulverinhalator
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9515182D0 (en) * 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
DE69705414T2 (de) * 1996-11-15 2002-05-02 Pathogenesis Corp., Seattle Reines, biologisch aktives colistin, seine bestandteile und eine colistin-zubereitung zur behandlung von entzündungen der atemwege
GB9626263D0 (en) * 1996-12-18 1997-02-05 Innovata Biomed Ltd Powder inhaler
JP3051073B2 (ja) * 1996-12-20 2000-06-12 住友林業株式会社 抗腫瘍活性物質
SE9700133D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
KR100436202B1 (ko) * 1997-02-12 2004-09-10 아이.엠.비 가부시키 가이샤 아가리쿠스버섯의자실체를배양하기위한인공균상재배방법과인공균상재배용배지및그재배방법에따라얻어진아가리쿠스버섯의자실체
US6465218B1 (en) * 1997-04-08 2002-10-15 Japan Applied Microbiology Research Institute Co., Ltd. Biologically active substance and process of preparing the same
EP0876814A1 (en) 1997-05-07 1998-11-11 "PHARLYSE", Société Anonyme Dry powder inhaler excipient, process for its preparation and pharmaceutical compositions containing it
US5980918A (en) * 1997-10-24 1999-11-09 Brennen Medical, Inc. β-D-glucan topical composition
GB9820746D0 (en) * 1998-09-23 1998-11-18 Pharmax Limited Micronised pharmaceutical compositions
US6120772A (en) * 1998-10-08 2000-09-19 Hitoshi Ito Oral drugs for treating AIDS patients

Also Published As

Publication number Publication date
EP1257260A1 (en) 2002-11-20
EP1129705A1 (en) 2001-09-05
DE60104399T2 (de) 2005-09-08
US20030053960A1 (en) 2003-03-20
WO2001060341A1 (en) 2001-08-23
DE60104399D1 (de) 2004-08-26
ATE271383T1 (de) 2004-08-15
AU2001236207A1 (en) 2001-08-27
EP1257260B1 (en) 2004-07-21
US7344734B2 (en) 2008-03-18

Similar Documents

Publication Publication Date Title
PT1257260E (pt) Formulacao de po
IL114596A0 (en) Pharmaceutical compositions for administration by inhalation
HK1096034A1 (en) A solid dosage form comprising a fibrate
AU2002316820A1 (en) Powder inhaler formulations
GEP20053473B (en) High Potency Dihydroergotamine Compositions
WO2001049274A3 (en) Methods for pulmonary delivery of interleukin-2
MY118151A (en) Pharmaceutical formulations containing voriconazole.
IL153297A0 (en) Compounds and compositions for delivering active agents
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
BG104877A (en) N-substituted anminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
EA200000584A2 (ru) Твердые фармацевтические композиции с контролируемым высвобождением, получаемые тепловым формованием
HK1076605A1 (en) Formulations
MXPA04007427A (es) Formulaciones de azitromicina granuladas por via seca.
ATE148630T1 (de) Stabilisierte derivate von vitamin d2 und d3 enthaltende pharmazeutische zusammensetzungen
NO20000466L (no) Farmasøytisk preparat for sure, lipofile forbindelser i form av en selvregulerende formulering
MXPA04003027A (es) Metodos para granulacion humeda de azitromicina.
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
WO2002015959A3 (en) Compounds and compositions for delivering active agents
PT1195160E (pt) Composições farmacêuticas de trimetazidina de libertação sustentada e método para a sua preparação
WO2005065639A3 (en) Novel pharmaceutical compositions
MXPA02011410A (es) Uso de compuestos 1-amino-5-fenilpentan-3-ol y/o 1-amino-6-fenilhexan-3-ol substituidos como medicamentos.
WO1999058527A3 (en) Benzofuran derivatives, pharmaceutical composition containing the same, and a process for the preparation of the active ingredient
WO2002020056A3 (en) Methods and compositions for producing a neurosalutary effect in a subject
AU2002220654A1 (en) Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders
IL140839A0 (en) Use of tiludronic acid and derivatives thereof in poultry for the preparation of a medicinal product for preventing and treating osteoporosis